We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Our knowledge, expertise & publications
Deals & Cases
20 July 2021
Kuros to receive USD 7m up front and retain the potential to receive up to USD 166.5m in future revenues under a royalty purchase agreement with XOMA Corporation related to Kuros’s license agreement with Checkmate Pharmaceuticals. VISCHER has been advising Kuros Biosciences AG in Swiss law matters along the US lead counsel. The VISCHER team is led by Matthias Staehelin with Sebastian Flückiger (both Corporate/M&A).
Categories: Intellectual Property, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Deals & Cases
Attorney at Law and Civil Law Notary
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the...
VISCHER advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51...
Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule...
Opt-in for our regular updates, news, views, insights and more.